119 related articles for article (PubMed ID: 18559971)
41. Effects of the angiotensin AT1 receptor blocker candesartan on myocardial ischemic/reperfusion injury.
Shimizu M; Sjöquist PO; Wang QD; Rydén L
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S137-42. PubMed ID: 9892154
[TBL] [Abstract][Full Text] [Related]
42. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
[TBL] [Abstract][Full Text] [Related]
43. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats.
Groth W; Blume A; Gohlke P; Unger T; Culman J
J Hypertens; 2003 Nov; 21(11):2175-82. PubMed ID: 14597862
[TBL] [Abstract][Full Text] [Related]
44. Angiotensin II blockade improves mitochondrial function in spontaneously hypertensive rats.
De Cavanagh EM; Toblli JE; Ferder L; Piotrkowski B; Stella I; Fraga CG; Inserra F
Cell Mol Biol (Noisy-le-grand); 2005 Nov; 51(6):573-8. PubMed ID: 16309582
[TBL] [Abstract][Full Text] [Related]
45. RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial.
Ahmed HA; Ishrat T; Pillai B; Fouda AY; Sayed MA; Eldahshan W; Waller JL; Ergul A; Fagan SC
J Neuroinflammation; 2018 Aug; 15(1):229. PubMed ID: 30103772
[TBL] [Abstract][Full Text] [Related]
46. Low-dose candesartan enhances molecular mediators of neuroplasticity and subsequent functional recovery after ischemic stroke in rats.
Ishrat T; Pillai B; Soliman S; Fouda AY; Kozak A; Johnson MH; Ergul A; Fagan SC
Mol Neurobiol; 2015; 51(3):1542-53. PubMed ID: 25084762
[TBL] [Abstract][Full Text] [Related]
47. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
London G; Schmieder R; Calvo C; Asmar R
Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
[TBL] [Abstract][Full Text] [Related]
48. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE).
Skoog I; Lithell H; Hansson L; Elmfeldt D; Hofman A; Olofsson B; Trenkwalder P; Zanchetti A;
Am J Hypertens; 2005 Aug; 18(8):1052-9. PubMed ID: 16109319
[TBL] [Abstract][Full Text] [Related]
49. Candesartan attenuates hypertension-associated pathophysiological alterations in the gut.
Wu D; Tang X; Ding L; Cui J; Wang P; Du X; Yin J; Wang W; Chen Y; Zhang T
Biomed Pharmacother; 2019 Aug; 116():109040. PubMed ID: 31170664
[TBL] [Abstract][Full Text] [Related]
50. Acute treatment with candesartan reduces early injury after permanent middle cerebral artery occlusion.
Guan W; Kozak A; El-Remessy AB; Johnson MH; Pillai BA; Fagan SC
Transl Stroke Res; 2011 Jun; 2(2):179-85. PubMed ID: 21904593
[TBL] [Abstract][Full Text] [Related]
51. Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke.
Kozak A; Ergul A; El-Remessy AB; Johnson MH; Machado LS; Elewa HF; Abdelsaid M; Wiley DC; Fagan SC
Stroke; 2009 May; 40(5):1870-6. PubMed ID: 19265050
[TBL] [Abstract][Full Text] [Related]
52. Synergism of amlodipine and candesartan on blood pressure reduction and organ protection in hypertensive rats.
Cheng YQ; Tan BY; Yu XH; Dong WZ; Su DF; Zhu DQ; Liu AJ
Clin Exp Pharmacol Physiol; 2018 Jun; 45(6):514-524. PubMed ID: 29193272
[TBL] [Abstract][Full Text] [Related]
53. Benefit of azilsartan on blood pressure elevation around rest-to-active phase in spontaneously hypertensive rats.
Isegawa K; Hirooka Y; Kishi T; Yasukawa K; Utsumi H; Sunagawa K
Clin Exp Hypertens; 2015; 37(1):45-50. PubMed ID: 24678965
[TBL] [Abstract][Full Text] [Related]
54. The effect of recombinant aminopeptidase A (APA) on hypertension in pregnant spontaneously hypertensive rats (SHRs).
Ishii M; Hattori A; Numaguchi Y; Ma X; Nagasaka T; Tsujimoto M; Murohara T; Kobayashi H; Mizutani S
Early Hum Dev; 2009 Sep; 85(9):589-94. PubMed ID: 19608358
[TBL] [Abstract][Full Text] [Related]
55. Innovative lipid-based carriers containing cationic derivatives of polyisoprenoid alcohols augment the antihypertensive effectiveness of candesartan in spontaneously hypertensive rats.
Gawryś O; Baranowska I; Gawarecka K; Świeżewska E; Dyniewicz J; Olszyński KH; Masnyk M; Chmielewski M; Kompanowska-Jezierska E
Hypertens Res; 2018 Apr; 41(4):234-245. PubMed ID: 29440705
[TBL] [Abstract][Full Text] [Related]
56. Renal Denervation in the Acute Phase of Ischemic Stroke Provides Brain Protection in Hypertensive Rats.
Hasegawa Y; Nakagawa T; Matsui K; Kim-Mitsuyama S
Stroke; 2017 Apr; 48(4):1104-1107. PubMed ID: 28246278
[TBL] [Abstract][Full Text] [Related]
57. Drug repurposing for vascular protection after acute ischemic stroke.
Guan W; Kozak A; Fagan SC
Acta Neurochir Suppl; 2011; 111():295-8. PubMed ID: 21725771
[TBL] [Abstract][Full Text] [Related]
58. Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral Ischemia.
Ishrat T; Soliman S; Eldahshan W; Pillai B; Ergul A; Fagan SC
Neurochem Res; 2018 Oct; 43(10):1869-1878. PubMed ID: 30088238
[TBL] [Abstract][Full Text] [Related]
59. Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion.
Mecca AP; O'Connor TE; Katovich MJ; Sumners C
Exp Physiol; 2009 Aug; 94(8):937-46. PubMed ID: 19429641
[TBL] [Abstract][Full Text] [Related]
60. Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke.
Fouda AY; Alhusban A; Ishrat T; Pillai B; Eldahshan W; Waller JL; Ergul A; Fagan SC
Mol Neurobiol; 2017 Jan; 54(1):661-670. PubMed ID: 26758277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
